“…[ 13 16 17 ] Newer anti-glaucoma medications such as netarsudil also affect the ocular surface with reticular macrocellular corneal edema. [ 18 ] Significant ocular surface disease in patients with glaucoma results in poorer quality of life and patient compliance to treatment adherence, worsening the vision-related quality of life in these patients. [ 19 ]…”